Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930418 | 0.81 | KCNQ2 (0.36) | GRM5DRD2DRD1PDE1BKCNH2 | |
| SCHEMBL19441926 | 0.79 | KCNH2 (0.45) | GRM5HTR1ADRD2DRD1DRD3 | |
| SCHEMBL14925525 | 0.74 | HTR6 (0.34) | — | |
| SCHEMBL14925540 | 0.74 | TLR9 (0.41) | DRD2DRD1DRD3 | |
| SCHEMBL25091834 | 0.73 | TLR9 (0.42) | PRKDC | |
| SCHEMBL24689500 | 0.71 | GRM5 (0.43) | GRM5KCNH2 | |
| SCHEMBL14925539 | 0.71 | RAD52 (0.41) | GRM5DRD2DRD1KCNH2 | |
| SCHEMBL10255561 | 0.70 | OGA (0.35) | — | |
| SCHEMBL18368357 | 0.69 | EGFR (0.38) | PDE1BKCNH2 | |
| SCHEMBL14925519 | 0.69 | GRM5 (0.40) | GRM5PDE1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-RE48239-E1 | Heteroaryl pyridone and aza-pyridone compounds | GENETECH, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190194203-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9782405-B2 | Heteroaryl pyridone and aza-pyrodine compounds | GENENTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-9238655-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-8921353-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194203-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | PRKDC 64/4885GRM5 2455/4885HTR1A 2065/4885 |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | PRKDC 64/4885GRM5 2455/4885HTR1A 2065/4885 |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | PRKDC 64/4885GRM5 2455/4885HTR1A 2065/4885 |
| US-20200062769-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PRKDC 118/4885GRM5 2006/4885HTR1A 2071/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PRKDC 118/4885GRM5 2006/4885HTR1A 2071/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | PRKDC 244/4885GRM5 2090/4885HTR1A 2091/4885 |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PRKDC 118/4885GRM5 2006/4885HTR1A 2071/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | PRKDC 244/4885GRM5 2090/4885HTR1A 2091/4885 |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PRKDC 118/4885GRM5 2006/4885HTR1A 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.